News|Articles|November 19, 2026

Cemdisiran Approved as First siRNA Therapy for Myasthenia Gravis

Listen
0:00 / 0:00

Key Takeaways

  • Cemdisiran is a complement C5–directed siRNA that lowers circulating C5 by inhibiting hepatic synthesis, representing a novel complement-inhibition mechanism in gMG compared with C5 protein blockade.
  • NIMBLE randomized 284 adults across 86 sites; cemdisiran monotherapy 600 mg every 12 weeks significantly improved MG-ADL (−2.3 placebo-adjusted) and QMG (2.8-point difference).
SHOW MORE

Given subcutaneously every 3 months, cemdisiran (Livsayis) is indicated for adults with AChR antibody–positive gMG and requires REMS enrollment.

The FDA has approved cemdisiran (Livsayis; Regeneron) for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody–positive, making it the first small interfering RNA (siRNA) therapy approved for the disease. Given subcutaneously 4 times a year, it is also the only FDA-approved gMG treatment on an every-3-month schedule, a dosing interval that could ease treatment burden but arrives with a boxed warning for serious meningococcal infections and a Risk Evaluation and Mitigation Strategy (REMS) that pharmacists will need to navigate.1

Regeneron announced the approval on November 18, 2026. Cemdisiran, licensed from Alnylam, is the company's first approved siRNA therapy and its first approved neurology medicine.1

A Different Way to Target C5

In AChR antibody–positive gMG, autoantibody-mediated complement activation drives disease pathology. Cemdisiran is a complement C5–directed siRNA that degrades the messenger RNA encoding C5, lowering circulating C5 and inhibiting terminal complement activation. Rather than blocking the C5 protein itself, the therapy inhibits hepatic C5 synthesis. In a commentary on the phase 3 trial, investigators from George Washington University noted that cemdisiran is the first complement inhibitor in myasthenia gravis to use this mechanism, entering a landscape that already included 3 FDA-approved complement inhibitors at the time of their writing.1-3

NIMBLE Trial Results

The approval was based on the phase 3 NIMBLE trial (NCT05070858), a randomized, double-blind, placebo-controlled study conducted at 86 centers in 13 countries. Of 284 adults randomly assigned, 79 received cemdisiran monotherapy at 600 mg every 12 weeks; other arms received pozelimab, a C5 antibody, alone or combined with cemdisiran, or placebo. Background immunosuppressants were permitted at investigator discretion.1,2

At week 24, cemdisiran reduced Myasthenia Gravis–Activities of Daily Living (MG-ADL) total score by a least-squares mean of 4.5 points vs 2.2 points with placebo (placebo-adjusted difference, −2.3; 95% CI, −3.6 to −1.0; P = .0005). Of patients receiving cemdisiran, 76.6% achieved at least a 3-point MG-ADL improvement versus 44.1% with placebo (P < .001). On the key secondary end point, the Quantitative Myasthenia Gravis (QMG) total score fell by 4.2 points with cemdisiran versus 1.5 points with placebo (placebo-adjusted difference, 2.8 points; P = .0015).1,2

According to Regeneron, improvements emerged as early as week 2 and were sustained through week 24. "Livsayis delivered rapid, deep disease control—maintained through the end of dosing intervals," said Tuan Vu, MD, professor of neurology at the University of South Florida Morsani College of Medicine and global principal investigator of NIMBLE.1

Safety, REMS, and Pharmacist Considerations

Cemdisiran carries a boxed warning for serious meningococcal infections. Patients must complete meningococcal vaccination at least 2 weeks before the first dose, and antibiotics are required if treatment must begin before vaccination. The label also warns of other serious infections, particularly those caused by encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae. The drug is contraindicated in patients with a serious meningococcal infection at the start of treatment.1

Cemdisiran is available only through the Livsayis REMS program, which requires enrollment, counseling, a Patient Guide, and a Patient Safety Card, giving pharmacists natural points to confirm vaccination status. The most common adverse reactions, occurring in at least 5% of patients and more often than with placebo, were injection site reactions, viral infections, and urinary tract infections. In the published trial, no serious or meningococcal infections occurred in the cemdisiran group during the double-blind period.1,2

Pharmacists should also note the scope of the label: the approved indication covers only adults who are anti-AChR antibody–positive, even though NIMBLE also enrolled patients with anti-LRP4 antibodies.1,2

REFERENCES
1. Livsayis (cemdisiran) approved by the FDA as first and only siRNA therapy in generalized myasthenia gravis. News release. Regeneron Pharmaceuticals; November 18, 2026. Accessed November 19, 2026. https://newsroom.regeneron.com/news-releases/news-release-details/livsayistm-cemdisiran-approved-fda-first-and-only-sirna-therapy
2. Vu T, Habib AA, Jacob S, et al; NIMBLE Trial Investigators. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2
3. Kusner LL, Kaminski HJ. Another complement inhibitor therapy for myasthenia gravis: Is it NIMBLE enough? Med. 2026;7(7):101186. doi:10.1016/j.medj.2026.101186

Related to this article